Medpace Holdings, Inc. (MEDP) Stock Score, Valuation & Financial Research
Medpace Holdings, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 44/100.
Quick answer for MEDP
Medpace Holdings, Inc. currently has a Wall Street Score of 44/100. The stored market price is $588.63. Its financial score is 54/100. Its valuation score is 13/100. These figures are a research snapshot, not a buy or sell recommendation.
What Medpace Holdings, Inc. does
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmac
MEDP financial snapshot
- Wall Street Score:
- 44/100
- Current price:
- $588.63
- Market capitalization:
- $16.43B
- Revenue:
- $2.78B
- Net income:
- $491.5M
- Free cash flow:
- $681.9M
- Cash:
- $502.7M
- Total debt:
- $120.1M
- EPS:
- 15.64
- P/E ratio:
- 37.6x
- Financial score:
- 54/100
- Valuation score:
- 13/100
- Revenue score:
- 34/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $681.9M, showing positive cash generation.
- The balance sheet shows $502.7M of cash versus $120.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 13/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 54/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MEDP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.